Yn y tair blynedd ers i astudiaeth PrEPARED gychwyn, rhagnodwyd PrEP i dros 1,200 o bobl ac ni fu dim diagnoses newydd o HIV o blith y bobl yng Nghymru sy’n cymryd PrEP.  Rydym wedi elwa hefyd o ddyfodiad fersiynau generig o PrEP sydd ar gael i’r GIG ar bris is o lawer na’r cynnyrch perchnogol.  Golyga hyn, gyda’r data dros dro a gasglwyd yn astudiaeth PrEPARED sy’n mynd i’r afael â pheth o’r ansicrwydd yn y gwerthusiad cychwynnol, fod AWMSG bellach wedi fy nghynghori bod PrEP yn debyg o fod yn gost-effeithiol ym mhob un senario, er gwaethaf unrhyw ansicrwydd sydd ar ôl.
In the three years since the PrEPARED study began, over 1,200 people have been prescribed PrEP and there have been no new diagnoses of HIV amongst people taking PrEP in Wales. We have also benefited from the emergence of generic versions of PrEP that are available to the NHS at a greatly reduced price when compared to the proprietary product. This, together with the interim data collected in the PrEPARED study addressing some of  the uncertainty in the initial appraisal, has meant AWMSG have now advised me that in all scenarios, PrEP is likely to be cost-effective, irrespective of any remaining uncertainties.